CUTANEOUS MELANOMA

This study is for people with high-risk melanoma who have had surgery to remove their cancer. Researchers are testing if a combination of two immunotherapy drugs works better than the current standard single drug at preventing the cancer from returning. They will use a special bl…

This early-stage trial is testing new combinations of targeted drugs for people with melanoma skin cancer that has spread to the brain. It aims to see if these drugs can shrink brain tumors in patients whose cancer has continued to grow despite prior immunotherapy. The study will…

This is a very early, first-in-human study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD204. It is for adults with advanced solid tumors (like lung, breast, or skin cancer) that have spread and have stopped responding to standard treatments…

This trial is testing new combinations of immunotherapy drugs given before surgery for patients with advanced melanoma who are predicted to respond poorly to standard treatments. The study involves 494 patients with stage 3 skin melanoma or mucosal melanoma that can be surgically…

This is a first-in-human study to find a safe dose of a new drug called MBS8 for people with advanced solid tumors that have stopped responding to standard treatments. The trial will test the drug alone and in combination with an existing immunotherapy in specific groups of melan…

This is a first-in-human study to test the safety and early effectiveness of a two-part treatment called IMA203 combined with mRNA-4203. It is for people with advanced skin cancer (melanoma) or a rare soft-tissue cancer (synovial sarcoma) that has spread and no longer responds to…

This study is testing a new oral drug, LNS8801, for people with advanced melanoma that has spread and no longer responds to standard immunotherapies. Researchers want to see if LNS8801, taken alone or combined with the drug pembrolizumab, can stop or slow cancer growth better tha…

This is the first study in people to test a new drug called AU-007 for advanced cancers that have spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the drug shows early signs of helping. It will be tested alone and in combination with other…

This study is testing a new drug called IDE196, both alone and combined with other drugs, for people with advanced cancers that have specific genetic changes (GNAQ/11 mutations or PRKC fusions). The main goals are to find safe doses and see if the treatments can shrink tumors. It…

This study is testing a new diagnostic platform that uses artificial intelligence to analyze small pieces of a patient's tumor. The goal is to predict whether a patient's cancer will respond to immunotherapy drugs before they start treatment. Researchers will compare the AI's pre…

This study is testing whether a numbing cream called EMLA can reduce the brief pain patients feel from injections during a lymph node mapping procedure for skin cancer. About 100 adults with melanoma, Merkel cell, or squamous cell skin cancer will be randomly assigned to use eith…

This study aims to understand how lifestyle factors like mental health, diet, exercise, and social support are linked to quality of life and health outcomes in people with melanoma. Researchers will enroll 5,000 patients who will complete questionnaires about their habits and wel…

This study aims to better understand how inherited changes in the BAP1 gene increase the risk for several types of cancer, including eye and skin melanoma, kidney cancer, and mesothelioma. Researchers will enroll 500 participants who have a personal or strong family history of th…

This study aims to understand if working outdoors increases the risk of developing specific types of skin cancer (melanoma) linked to long-term sun exposure. Researchers in Modena, Italy, will interview 300 patients who have had a skin biopsy. They will compare the work and sun e…

This study aims to understand the side effects that melanoma patients experience while receiving immunotherapy drugs. Researchers will follow 300 patients over time to track their symptoms, identify patterns, and learn what factors might make side effects worse. The goal is to ga…